387 related articles for article (PubMed ID: 29436696)
21. The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models.
Gravina GL; Mancini A; Colapietro A; Vitale F; Vetuschi A; Pompili S; Rossi G; Marampon F; Richardson PJ; Patient L; Patient L; Burbidge S; Festuccia C
Tumour Biol; 2017 Jun; 39(6):1010428317695528. PubMed ID: 28639900
[TBL] [Abstract][Full Text] [Related]
22. Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis.
Matsusue R; Kubo H; Hisamori S; Okoshi K; Takagi H; Hida K; Nakano K; Itami A; Kawada K; Nagayama S; Sakai Y
Ann Surg Oncol; 2009 Sep; 16(9):2645-53. PubMed ID: 19588204
[TBL] [Abstract][Full Text] [Related]
23. Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy.
Salomonnson E; Stacer AC; Ehrlich A; Luker KE; Luker GD
PLoS One; 2013; 8(1):e51500. PubMed ID: 23372646
[TBL] [Abstract][Full Text] [Related]
24. Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis.
Teng F; Tian WY; Wang YM; Zhang YF; Guo F; Zhao J; Gao C; Xue FX
J Hematol Oncol; 2016 Feb; 9():8. PubMed ID: 26851944
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis.
Yang F; Takagaki Y; Yoshitomi Y; Ikeda T; Li J; Kitada M; Kumagai A; Kawakita E; Shi S; Kanasaki K; Koya D
Cancer Res; 2019 Feb; 79(4):735-746. PubMed ID: 30584072
[TBL] [Abstract][Full Text] [Related]
26. Curcumin protects against hepatic stellate cells activation and migration by inhibiting the CXCL12/CXCR4 biological axis in liver fibrosis:A study in vitro and in vivo.
Qin L; Qin J; Zhen X; Yang Q; Huang L
Biomed Pharmacother; 2018 May; 101():599-607. PubMed ID: 29518606
[TBL] [Abstract][Full Text] [Related]
27. CXCR4-Targeted and Redox Responsive Dextrin Nanogel for Metastatic Breast Cancer Therapy.
Zhang F; Gong S; Wu J; Li H; Oupicky D; Sun M
Biomacromolecules; 2017 Jun; 18(6):1793-1802. PubMed ID: 28445650
[TBL] [Abstract][Full Text] [Related]
28. CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.
Gil M; Komorowski MP; Seshadri M; Rokita H; McGray AJ; Opyrchal M; Odunsi KO; Kozbor D
J Immunol; 2014 Nov; 193(10):5327-37. PubMed ID: 25320277
[TBL] [Abstract][Full Text] [Related]
29. Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.
Hsiao JJ; Ng BH; Smits MM; Wang J; Jasavala RJ; Martinez HD; Lee J; Alston JJ; Misonou H; Trimmer JS; Wright ME
BMC Cancer; 2015 Mar; 15():204. PubMed ID: 25884570
[TBL] [Abstract][Full Text] [Related]
30. MTSS1 inhibits colorectal cancer metastasis by regulating the CXCR4/CXCL12 signaling axis.
Chen L; Chen Q; Wu Y; Zhu M; Hu J; Zhuang Z
Int J Mol Med; 2021 May; 47(5):. PubMed ID: 33649808
[TBL] [Abstract][Full Text] [Related]
31. Targeting the CXCR4/CXCL12 axis in treating epithelial ovarian cancer.
Mao TL; Fan KF; Liu CL
Gene Ther; 2017 Oct; 24(10):621-629. PubMed ID: 28753202
[TBL] [Abstract][Full Text] [Related]
32. CXCL12 induces hepatic stellate cell contraction through a calcium-independent pathway.
Saiman Y; Agarwal R; Hickman DA; Fausther M; El-Shamy A; Dranoff JA; Friedman SL; Bansal MB
Am J Physiol Gastrointest Liver Physiol; 2013 Sep; 305(5):G375-82. PubMed ID: 23812037
[TBL] [Abstract][Full Text] [Related]
33. Stem cell autocrine CXCL12/CXCR4 stimulates invasion and metastasis of esophageal cancer.
Wang X; Cao Y; Zhang S; Chen Z; Fan L; Shen X; Zhou S; Chen D
Oncotarget; 2017 May; 8(22):36149-36160. PubMed ID: 28193907
[TBL] [Abstract][Full Text] [Related]
34. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
Zheng N; Liu W; Chen J; Li B; Liu J; Wang J; Gao Y; Shao J; Jia L
Mol Carcinog; 2019 Jan; 58(1):144-155. PubMed ID: 30259564
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.
Morimoto M; Matsuo Y; Koide S; Tsuboi K; Shamoto T; Sato T; Saito K; Takahashi H; Takeyama H
BMC Cancer; 2016 May; 16():305. PubMed ID: 27175473
[TBL] [Abstract][Full Text] [Related]
36. Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo.
Beider K; Darash-Yahana M; Blaier O; Koren-Michowitz M; Abraham M; Wald H; Wald O; Galun E; Eizenberg O; Peled A; Nagler A
Mol Cancer Ther; 2014 May; 13(5):1155-69. PubMed ID: 24502926
[TBL] [Abstract][Full Text] [Related]
37. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
Xue J; Li R; Gao D; Chen F; Xie H
Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
[TBL] [Abstract][Full Text] [Related]
38. Involvement of CXCL12/CXCR4 axis in colorectal cancer: a mini-review.
Bocchi M; de Sousa Pereira N; de Oliveira KB; Amarante MK
Mol Biol Rep; 2023 Jul; 50(7):6233-6239. PubMed ID: 37219666
[TBL] [Abstract][Full Text] [Related]
39. SEMA3F prevents metastasis of colorectal cancer by PI3K-AKT-dependent down-regulation of the ASCL2-CXCR4 axis.
Zhou ZH; Rao J; Yang J; Wu F; Tan J; Xu SL; Ding Y; Zhan N; Hu XG; Cui YH; Zhang X; Dong W; Liu XD; Bian XW
J Pathol; 2015 Aug; 236(4):467-78. PubMed ID: 25866254
[TBL] [Abstract][Full Text] [Related]
40. KIT Exon 11 Codons 557-558 Deletion Mutation Promotes Liver Metastasis Through the CXCL12/CXCR4 Axis in Gastrointestinal Stromal Tumors.
Wang HC; Li TY; Chao YJ; Hou YC; Hsueh YS; Hsu KH; Shan YS
Clin Cancer Res; 2016 Jul; 22(14):3477-87. PubMed ID: 26936919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]